According to WHO studies, approximately 170 million individuals of
the world population are diagnosed to be infected with Hepatitis C
virus. Unfortunately around 20 % of these patients experience
progressive liver disease leading to cirrhosis or hepatocellular
carcinoma over 20 to 40 years. Interferon-alpha and ribavirin
combination therapy is the standard treatment for chronic hepatitis
C. These drugs may trigger production of different types of
non-specific and specific autoantibodies. Thyroid dysfunction,
which has been reported to occur from 3.9-33.33%, is the most
common autoimmune disorder associated with combination therapy.
Therefore, it is necessary that thyroid functions are monitored
during therapy and the course of thyroid disease is watched for
once autoimmune thyroid disorder develops. This book highlights the
effects of Interferon and ribavirin on thyroid functions, its
pathogenesis, clinical features and outcome through a cohort study
carried out on chronic hepatitis C patients.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!